Latest News - Earnings & Financials

Wednesday, October 18, 2017 | Earnings & Financials

Gemini Therapeutics Announces $42.5 Million Series A Financing to Develop Precision Therapeutics in Ophthalmology and Rare Genetic Diseases

Gemini Therapeutics, a new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, announced that it has completed a …

Read the full story

Wednesday, October 11, 2017 | Earnings & Financials

Azura Ophthalmics Receives $16 Million in Series B Funding to Develop Treatment for Leading Cause of Dry Eye Disease

Azura Ophthalmics announced it has completed a $16 million Series B funding that will enable Azura to advance development of drug therapy for meibomian gland dysfunction (MGD) to the next stage o…

Read the full story

Wednesday, October 11, 2017 | Earnings & Financials

Biophytis Completes a €10.4 M Capital Increase to Finance Mid-Stage Clinical Trials for Two Anti-Aging Drug-Candidates

Biophytis announced entry into definitive agreements for a €10.4 million capital raise to fund the its clinical development in age-related diseases, such as Sarcopenia and dry age-related macular…

Read the full story

Friday, October 06, 2017 | Earnings & Financials, Retina, AMD

PanOptica Secures Funding to Advance Clinical Development of PAN-9080 Topical Anti-VEGF Eye Drop

PanOptica announced that it has secured $11 million in a Series B financing to enable clinical advancement of PAN-90806, a small molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop f…

Read the full story

Thursday, October 05, 2017 | Earnings & Financials

Omeicos Secures Extension of Series B Financing Round to Expand its Technology into Ophthalmology

Omeicos Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases, announced that it has …

Read the full story

Tuesday, September 26, 2017 | Earnings & Financials, Allergan

Allergan Authorizes New $2 Billion Share Repurchase Program

Allergan announced that the company's board of directors has authorized a new $2 billion share repurchase program, and has affirmed its commitment to increasing its regular quarterly cash dividend…

Read the full story

Friday, September 01, 2017 | Earnings & Financials, Retina, NightstaRx

Nightstar Files Registration Statement For Proposed Initial Public Offering

Nightstar Therapeutics a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, announced that it has filed a registration statement on Form F-1 with the U.S. S…

Read the full story

Tuesday, August 08, 2017 | Earnings & Financials, Aerie Pharmaceuticals

Aerpio Pharmaceuticals Commences Trading on the OTCQB Market

Aerpio Pharmaceuticals announced that shares of the company’s common stock have been cleared for trading on the OTC Market Group's OTCQB market in the United States. Shares of Aerpio’s…

Read the full story

Friday, August 04, 2017 | Earnings & Financials, Regeneron Pharmaceuticals

Regeneron's Second-Quarter Revenue Rises 21 Percent on Higher Eylea Sales

Regeneron Pharmaceuticals announced that revenue for the second quarter jumped 21 percent to $1.5 billion, beating analyst estimates of $1.4 billion, fuelled by 11-percent growth in Eyl…

Read the full story

Wednesday, July 26, 2017 | Clinical Trials, Earnings & Financials, AMD, Ophthotech

Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases

Ophthotech announced that the company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for…

Read the full story

Wednesday, July 26, 2017 | Earnings & Financials, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters’ Option

Kala Pharmaceuticals announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters’ exercise in full of their option to purchase an additio…

Read the full story

Monday, July 24, 2017 | Earnings & Financials, Allegro Ophthalmics

Allegro Ophthalmics Secures $10.7 Million in Private Financing

Allegro Ophthalmics announced the completion of a private round of equity financing for $10.7 million. With this infusion of capital, the company is positioned to reach future corporate milestones. Th…

Read the full story

Thursday, July 20, 2017 | Earnings & Financials, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Pricing of Initial Public Offering

Kala Pharmaceuticals announced that is has priced its initial public offering of 6,000,000 shares of its common stock at a public offering price of $15 per share, for aggregate gross proceeds of appro…

Read the full story

Tuesday, July 18, 2017 | Earnings & Financials, Alcon

Latest Novartis Earnings Show Signs of a Rebound at Alcon

As part of its second quarter earnings, Novartis reported that sales at its Alcon unit accelerated in the second quarter. Novartis Chief Executive Joe Jimenez said the results increase the number of o…

Read the full story

Tuesday, June 27, 2017 | Earnings & Financials

NuEyes Secures Funding by Early Stage Venture Capital Firm, Arab Angel and Strategic Partners

NuEyes Technologies announced that it has secured a round of funding to fuel its growth in helping the legally blind live more independent lives. NuEyes works closely with ODG (Osterhout Design G…

Read the full story
Load More